Rein Therapeutics slips on FDA clinical hold for lung disease drug

Shares of drug developer Rein Therapeutics RNTX.O fall 9.8% to $1.74

Late on Thursday, the U.S. FDA put a clinical hold on co's mid-stage trial of LTI-03, a lung disease drug - SEC filing

Patient enrollment and dosing have been paused in the U.S.

Co said it is working with the FDA to resolve the issue and lift the hold

The trial is still ongoing in Australia and Europe

Including session move, stock down 21.7% YTD